文献速递精神分裂症与精神病性障碍

甘氨酸转运体1抑制剂PF-03463275的剂量相关靶点占据及对环路、行为和神经可塑性的影响

Dose-Related Target Occupancy and Effects on Circuitry, Behavior, and Neuroplasticity of the Glycine Transporter-1 Inhibitor PF-03463275 in Healthy and Schizophrenia Subjects.
PubMed 文献 · Biol Psychiatry · 2018-01-31

本研究在健康受试者和精神分裂症患者中评估GlyT1抑制剂PF-03463275的剂量相关靶点占据及对工作记忆环路、长时程增强和神经可塑性的影响。结果显示GlyT1占据率随剂量线性增加,药物未减弱氯胺酮诱导效应但改善健康对照工作记忆准确性和患者神经可塑性,支持开展认知矫正临床试验。

要点

  • PF-03463275的GlyT1占据率随剂量线性增加,60mg每日两次达约83%。
  • 药物未减弱氯胺酮诱导的工作记忆环路激活破坏,但改善健康对照工作记忆准确性。
  • 仅在精神分裂症患者中增强长时程增强,峰值效应在40mg每日两次,呈倒U型剂量反应。

核心结论

  • PF-03463275的剂量相关GlyT1占据呈线性,虽未在氯胺酮试验中促进NMDA受体功能,但在精神分裂症患者中增强神经可塑性,支持开展认知矫正临床试验。

研究设计与样本

  • 研究分为两个子研究:子研究1在精神分裂症患者和健康对照中测试PF-03463275(10、20、40mg每日两次)的GlyT1占据(PET和18F-MK-6577)及视觉长时程增强,并仅在健康对照中测试药物减弱氯胺酮诱导工作记忆环路激活破坏的能力(fMRI);子研究2仅在精神分裂症患者中检查60mg每日两次的GlyT1占据和长时程增强。

主要发现

  • PF-03463275在10、20、40、60mg每日两次时,精神分裂症患者的GlyT1占据率分别约为44%、61%、76%、83%,且皮质下区域配体结合高于皮质区域。
  • PF-03463275未减弱任何氯胺酮诱导效应,但改善了健康对照的工作记忆准确性。
  • PF-03463275仅在精神分裂症患者中增强长时程增强,峰值效应在40mg每日两次(约75% GlyT1占据),呈倒U型剂量反应。
  • PF-03463275耐受性良好。

临床怎么用

  • PF-03463275在精神分裂症患者中增强神经可塑性且耐受性良好,可支持开展临床试验以测试其增强认知矫正、改善精神分裂症相关认知损害的能力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glycine transporter-1 (GlyT1) inhibitors may ameliorate cognitive impairments associated with schizophrenia. The dose-related occupancy and target engagement of the GlyT1 inhibitor PF-03463275 were studied to inform optimal dose selection for a clinical trial for cognitive impairments associated with schizophrenia. METHODS: In substudy 1, the effects of PF-03463275 (10, 20, and 40 mg twice a day) on occupancy of GlyT1 were tested using positron emission tomography and 18F-MK-6577, and visual long-term potentiation (LTP) in schizophrenia patients (SZs) and healthy control subjects. Furthermore, the capacity of PF-03463275 to attenuate ketamine-induced disruption of working memory-related activation of a "working memory" circuit was tested only in healthy control subjects using functional magnetic resonance imaging. Subsequently, the effects of PF-03463275 (60 mg twice a day) on occupancy of GlyT1 and long-term potentiation were examined only in SZs (substudy 2). RESULTS: PF-03463275 at 10, 20, 40, and 60 mg twice a day produced ∼44%, 61%, 76%, and 83% GlyT1 occupancy, respectively, in SZs with higher ligand binding to GlyT1 in subcortical versus cortical regions. PF-03463275 did not attenuate any ketamine-induced effects but did improve working memory accuracy in healthy control subjects. PF-03463275 increased long-term potentiation only in SZs with peak effects at 40 mg twice a day (∼75% GlyT1 occupancy) and with a profile suggestive of an inverted U dose response. PF-03463275 was well-tolerated. CONCLUSIONS: The dose-related GlyT1 occupancy of PF-03463275 is linear. While PF-03463275 did not show evidence of facilitating N-methyl-D-aspartate receptor function in the ketamine assay, it enhanced neuroplasticity in SZs. These findings provide support for a clinical trial to test the ability of PF-03463275 to enhance cognitive remediation toward addressing cognitive impairments associated with schizophrenia.

来源:Biol Psychiatry,查看原文。版权归原作者所有。

引用

  1. D'Souza DC, Carson RE, Driesen N, et al. Dose-Related Target Occupancy and Effects on Circuitry, Behavior, and Neuroplasticity of the Glycine Transporter-1 Inhibitor PF-03463275 in Healthy and Schizophrenia Subjects. Biol Psychiatry. 2018. PMID: 29499855. doi:10.1016/j.biopsych.2017.12.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。